This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Improved outcomes in late-stage skin cancer revealed by new Scancell data

Improved outcomes in late-stage skin cancer revealed by new Scancell data

23 Jul 2025

Scancell, a clinical stage biotechnology company based at The Oxford Science Park, has announced further positive data from its ongoing Phase 2 SCOPE trial of immunotherapies targeting advanced tumours that cannot be removed surgically. The overall response rate to iSCIB1+, a modified version of Scancell’s lead product (SCIB1) from its DNA Immunobody® platform, was 69% for target HLA type patients, representing 80% of total patients - greatly... Read more

Evox Therapeutics Expands Scientific Advisory Board

Evox Therapeutics Expands Scientific Advisory Board

18 Jul 2025

Evox Therapeutics Ltd, a biotechnology company developing innovative therapies for rare, genetically driven neurodegenerative diseases using a next-generation gene editing modality, today announced the appointment of three world-class scientists to its Scientific Advisory Board (SAB). These appointments come as Evox advances a focused pipeline of transformative gene editing therapies targeting the MSH3 gene for the treatment of Huntington’s... Read more

Saudi and UK Ministers visit The Oxford Science Park

Saudi and UK Ministers visit The Oxford Science Park

14 Jul 2025

The Oxford Science Park welcomed Lord Vallance, UK Minister of State for Science, Research and Innovation, alongside His Excellency Abdullah Alswaha, Saudi Arabia’s Minister of Communications and Information Technology, for a visit last Friday aimed at fostering future scientific collaboration and investment between the UK and the Kingdom of Saudi Arabia. During their visit, the ministers engaged with senior executives from some of the Park’s... Read more

Ochre Bio appoints Quin Wills as CEO

Ochre Bio appoints Quin Wills as CEO

02 Jul 2025

Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease based at The Oxford Science Park, has appointed Dr Quin Wills as CEO.  As Founder of Ochre Bio, and previously CSO, Quin has been driving the company’s innovative approach to late-stage liver disease, developing potential new therapeutics to target disease progression. Quin will now lead the company in the next phase of its ambitions: progressing new drug... Read more

Oxford Science Park cancer experts honoured at inaugural Cancer Vaccine Awards

Oxford Science Park cancer experts honoured at inaugural Cancer Vaccine Awards

02 Jul 2025

Two prominent cancer experts based at The Oxford Science Park have been recognised at the UK’s first-ever Cancer Vaccine Awards Ceremony, which celebrated outstanding contributions to cancer vaccine science and clinical innovation across the country. Professor Lindy Durrant, founder and CSO of Scancell, which is headquartered at The Oxford Science Park, received the Innovation in Cancer Vaccine Development award. Her pioneering breakthroughs... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More